The leader in the pharmaceutical market of Serbia and the region and one of the top ten exporters in Serbia, company Hemofarm celebrated 58 years of successful business.
During the previous year, Hemofarm achieved new business successes and became the main centre of the Stada Group, within which it operates, for the markets of Central Europe (Poland, Czech Republic and Slovakia), thus expanding the regional jurisdiction zone to a total of 13 Central and Southeast European countries. The construction of the state-of-the-art Packaging Center in Vršac has been successfully completed, in which € 21.6 million was invested, while a new plant for the production of sterile nasal sprays (SNUP) was built in Podgorica’s Hemomont.
Since August 2006, since Hemofarm has been owned by the German Stada Group, some EUR 300 million has been invested in modernising business, equipment and new plants, and new investments have been planned.
“I am proud that we have maintained our leading position in Serbia, Bosnia and Herzegovina and Montenegro, and we are making strong progress in other markets as well. Being a market leader is the goal of every company, but perhaps the toughest task is to maintain a leadership position. Nevertheless, decades of successful business have taught us how to be and remain the best – we constantly strive for modernisation, and we are ready to adapt at the same time to the demands of local markets and global business conditions. We try to be new and different, so I can say that Hemofarm possesses the wisdom of a mature man and enthusiasm for teenagers, ” said Ronald Seeliger, general manager of Hemofarm.
The plans of Hemofarm are closely linked to the further strengthening and internationalisation of the Stada business, whose intention is to become one of the five largest manufacturers of generic drugs in the world.
